



IX Congresso Internacional de  
**Uro-Oncologia**

IV SIMPÓSIO MULTIPROFISSIONAL DE URO-ONCOLOGIA

# ASCO GU 2018 Renal cancer

---

BEST ABSTRACTS

Dr. Felipe Moraes

Oncologista Clínico

BP – A Beneficência Portuguesa de SP



>100 abstracts...

What we need to know?

# Summary

---

Biomarkers, prognostic and predictive issues

Surgery

Adjuvant setting

Metastatic setting

News drugs



# Summary

---

Biomarkers, prognostic and predictive issues

Surgery

Adjuvant setting

Metastatic setting

News drugs







Paguei uma nota e... Nada!

# Sorry... nothing amazing

---

**Systemic immune inflammation index and treatment response in patients with metastatic renal cell cancer.**

*Kadriye Bir*

**Self-reported quality of life as a predictor of survival in renal cell carcinoma**

*Ridwan Alam.*

**Prognostic and predictive role of fumarate hydratase in metastatic clear cell renal cell carcinoma.**

*Claudio Vernieri,*

**Incorporation of *PBRM1*, *BAP1*, *TP53* mutation status into the Memorial Sloan Kettering Cancer Center (MSKCC) risk model: A genomically annotated tool to improve stratification of patients (pts) with advanced renal cell carcinoma (RCC).**

*Martin Henner Voss,*

# summary

---



Biomarkers, prognostic and predictive issues

Surgery

Adjuvant setting

Metastatic setting

News drugs



# Surgery

---



**Trends and morbidity for minimally invasive versus open cytoreductive nephrectomy in the management of metastatic renal cell carcinoma.**

*Dimitar V. Zlatev*

Dados retrospectivos 2003-2015  
24145 pacientes  
SO aberta x laparoscopica x robotica



Menos tempo de UTI e transfusao com tecnica minimante invasivas  
Laparoscopia com melhor relacao custo-beneficio  
Reducao de 30% em complicacoes nos primeiros 90 dias.



# Surgery

---



**Does treatment approach for small renal masses affect survival in patients 70 years old?**

*Lukas Hockman,*

10477 pacientes idosos  
Observacao x Ressecao ou ablacao  
Retrospectivos



Aparente beneficio em OS. Medida em OS e 10 anos  
Ablacao: 97% - 96%  
Observacao: 83% - 74%  
Cirurgia: 96% - 94%

# Surgery

---

**Survival following upfront cytoreductive nephrectomy versus targeted therapy for metastatic renal cell carcinoma.**

*Bimal Bhindi*

15068 pacientes  
com dados  
retrospectivos  
NCBD  
Upfront x TT first



OS: 16.5 meses x 9 meses  
HR 0.62 (95%CI 0.61 x 0.64)

# Surgery

*Jeffrey Graham*

## Cytoreductive nephrectomy in metastatic papillary renal cell carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC).

353 pacientes, estudio retrospectivo multicentrico.


OS CN: 16.3meses (95%CI: 13.1-19.2) X No CN: 8.6meses (95%CI: 6.1-12.2)

	No CN (n = 109)	CN (n = 244)	p value
Median Age	67 years	59 years	0.0001
KPS < 80	28/90 (31%)	41/214 (19%)	0.0231
Diagnosis to therapy < 1 year	99/109 (91%)	204/244 (84%)	0.0723
Calcium > ULN	16/89 (18%)	30/193 (16%)	0.6072
Hemoglobin < LLN	69/99 (70%)	136/216 (63%)	0.2445
Neutrophils > ULN	25/98 (26%)	38/209 (18%)	0.1383
Platelets > ULN	26/98 (27%)	42/213 (20%)	0.1769
Brain metastases	3/106 (2.8%)	5/204 (2.5%)	0.8417
Sarcomatoid histology	0/89	31/215 (14%)	0.0002

HR: 0,62  
(0.45-0.85)

# summary

---



Biomarkers...

Surgery

Adjuvant setting

Metastatic setting

News drugs



# Adjuvant setting

---

**Defining individual recurrence risk following surgery for high risk non-metastatic renal cell carcinoma.**

*Edwin J Abel,*

771 pacientes  
Estudo multicentrico  
Identificou fatores de  
risco de recorrência




Diametro > 7cm  
Necrose  
GN 4  
Componente  
sarcomatoide

# Adjuvant therapy

Lauren Christine Harshman

**A phase III randomized study comparing perioperative nivolumab vs. observation in patients with localized renal cell carcinoma undergoing nephrectomy (PROSPER RCC).**



**Phase 3, randomized, double-blind trial of pembrolizumab in the adjuvant treatment of renal cell carcinoma (RCC): KEYNOTE-564.** *David I. Quinn*

# Adjuvant therapy

---



**Phase 3, randomized, double-blind trial of pembrolizumab in the adjuvant treatment of renal cell carcinoma (RCC): KEYNOTE-564.** *David I. Quinn*

# Adjuvant therapy

*Daniel Vargas Almeida*

**Meta-analysis of randomized clinical trials (RCT) for the adjuvant treatment of high-risk clear cell renal carcinoma (RCC) with vascular endothelial growth factor receptor tyrosine-kinase inhibitors (VEGFR TKIs).**



**Conclusions:** This meta-analysis failed to demonstrate a statistically significant improvement in DFS of RCC patients treated with adjuvant VEGFR TKI. However, a statistically significant improvement in DFS was observed when only patients with clear cell histology were evaluated. Longer follow-up of the ongoing trials is necessary in order to better evaluate the impact on overall survival.



# Summary

---

Biomarkers...

Surgery


Adjuvant setting

Metastatic setting

News drugs



# First line



Boxed categories represent strong recommendations




Tratamento do Câncer de Rim ECIV



# First Line

*Robert J. Motzer,*

## IMmotion151: A Randomized Phase III Study of Atezolizumab Plus Bevacizumab vs Sunitinib in Untreated Metastatic Renal Cell Carcinoma (mRCC)



study showed longer PFS for atezo + bev vs sun in PD-L1+ pts. Improved PFS was also observed in ITT pts. Safety was consistent with that of the individual agents. These results support the use of atezo + bev as a 1L treatment option in mRCC. Clinical trial information: NCT02420821.



# First Line

*Robert J. Motzer,*

## IMmotion151: A Randomized Phase III Study of Atezolizumab Plus Bevacizumab vs Sunitinib in Untreated Metastatic Renal Cell Carcinoma (mRCC)

	Coprimary		Secondary	
	PD-L1+ n = 362		ITT N = 915	
	Sun n = 184	Atezo + Bev n = 178	Sun n = 461	Atezo + Bev n = 454
mPFS, mo	7.7	11.2	8.4	11.2
95% CI	6.8, 9.7	8.9, 15.0	7.5, 9.7	9.6, 13.3
Stratified HR		0.74		0.83
95% CI		0.57, 0.96		0.70, 0.97
		P= 0.0217		P = 0.0219 <sup>a</sup>
ORR, %	35	43	33	37
95% CI	28, 42	35, 50	29, 38	32, 41
DOR, mo	12.9	NE	14.2	16.6
95% CI	9.8, NE	12.4, NE	11.3, NE	15.4, NE


NE, not estimable <sup>a</sup> Descriptive purposes only

**COMING SOON**

# First Line – phase I

*Michael B. Atkins,*

**Safety and efficacy of axitinib (axi) in combination with pembrolizumab (pembro) in patients (pts) with advanced renal cell cancer (aRCC).**




with 6 treatment-unrelated deaths reported. **Conclusions:** The combination axi/pembro is tolerable and exhibits promising antitumour activity in treatment-naïve pts with aRCC. A randomized phase 3 trial comparing the combination to sunitinib monotherapy is underway. Clinical trial information: NCT02133742.

# First Line... loading

*Robert J. Motzer,*

**A phase 3 trial to compare efficacy and safety of lenvatinib in combination with everolimus or pembrolizumab versus sunitinib alone in first-line treatment of patients with metastatic renal cell carcinoma.**





# Summary

---

Biomarkers, prognostic and predictive issues

Surgery

Adjuvant setting

Metastatic setting

News drugs



# New drugs

---

Inibidor de glutaminase

27 pacientes previamente tratados.  
1PR / 21SD/ PFS: 7.1meses. G3: Fadiga:11%/ Hiperglicemia:7%/ Neutropenia:7%

**Phase 1 study of glutaminase (GLS) inhibitor CB-839 combined with either everolimus (E) or cabozantinib (Cabo) in patients (pts) with clear cell (cc) and papillary (pap) metastatic renal cell cancer (mRCC).** *Nizar M. Tannir,*

Sitravatinibe

TKI em associacao com imuno... Em segunda linha...

**A phase I/II study of sitravatinib (MGCD-516) plus nivolumab in patients (pts) with metastatic clear-cell renal cell carcinoma (ccRCC) that progressed on prior VEGF-targeted therapy.**

*Pavlos Msaouel*


Tivozanibe

18 pacientes.  
Hipertensao, anemia e mucosite. TKI mais seletivo. Terapia tripla em primeira linha?

**Tivozanib combined with nivolumab: Phase Ib/II study in metastatic renal cell carcinoma (mRCC)**

*Bernard Escudier,*

# New drugs



Terapia celular

9 pacientes tratados. Preparo de células dendríticas para CAIX target  
Apenas 01 resposta estável. Mais importante pela sua factibilidade.

**A phase I, open-label, dose-escalation and cohort expansion study evaluating the safety and immune response to autologous dendritic cells transduced with AdGMCA9 in patients with metastatic renal cell carcinoma.**

*Izak Faiena*

# New drugs

---

Selenio

9 pacientes tratados. Molécula de down-regulation de oncogenes  
Aparentemente segura em associação com axitinibe

**Phase 1 clinical trial of high doses of Seleno-L-methionine (SLM), in sequential combination with axitinib in previously treated and relapsed clear cell renal cell carcinoma (ccRCC) patients.**

*Yousef Zakharia,*





# New drugs

---

Pexa-vec

9 pacientes tratados. Molécula de down-regulation de oncogenes  
Aparentemente segura em associação com axitinibe

**Phase II trial of pexa-vec (*pexastimogene devacirepvec*; JX-594), an oncolytic and immunotherapeutic vaccinia virus, in patients with metastatic, refractory renal cell carcinoma (RCC).**

*Seong-Geun Kim*

CRIZO

*Patrick Schoffski,*

**Effect of crizotinib on disease control in patient with advanced papillary renal cell carcinoma type 1 with MET mutations or amplification: Final results of EORTC 90101 CREATE.**

Melhores resultados que os controles históricos com uso de QT, poucos pacientes

In the MET+ patients (n=4), 2 achieved a partial response and 1 had stable disease (ORR 50%; 95% CI: 6.8-93.7%). One year overall survival was 75.0%

# Thanks...

---

Contact: [felipe73.moraes@gmail.com](mailto:felipe73.moraes@gmail.com)



BP Mirante - Oncology Center.